Page 1697 - Clinical Small Animal Internal Medicine
P. 1697
Index 1635
clinical manifestations of spinal cord dysfunction 818–819 SRD see steroid‐responsive diarrhea
VetBooks.ir clinical manifestations of clinical assessment 742–744, SRT see stereotactic radiation
spinal cord injury (SCI) 741–748
hypernatremia 1074–1075
SRS see stereotactic radiosurgery
therapy
hyponatremia 1072–1073
743–744
concepts and definitions 1069 instability of the vertebral SSI see surgical site infections
consequences of chronic column 742, 742 stabilization techniques 744–745,
hypernatremia 1075 myelopathy 815–822 745, 746–747, 746, 747
consequences of chronic pathophysiology 741–742, 742 Staphylococcus spp. 1059
hyponatremia 1073 prognosis 748 bacterial pyodermas 1461–1465,
endocrine manifestations of trauma and burns 446 1462, 1465, 1467–1470
cancer 1214 treatment 744–747, 745, urolithiasis 1136
fluid therapy 362 745–746, 747 valvular heart disease 250
forebrain disorders 777–778 spinal cord neoplasia see central S. aureus phage lysate therapy 1470
heart failure 193 nervous system tumors Starling’s law 176, 333–334, 334,
hypernatremia 777–778, 1069, spinal reflexes 732–733, 818 357, 413
1074–1076 spinal shock 818 statins 599
hypoadrenocorticism 82, 85 spinning‐disc interferometry 910 statistical analysis 7–16
hyponatremia 193, 778, 1069, spirocercosis 319, 1283–1284, 1333 clinical decision making 25
1071–1074, 1097–1098 splenectomy 1366 cumulative incidence 13–14
management of hypernatremia splenomegaly 707 describing data
1075–1076 splints 747 distributions 10–12, 11–13
management of hyponatremia sporotrichosis 998–999 external validity 7–8
1073–1074 diagnosis 999 hypothesis testing 8–10
osmoregulation and volume epidemiology and signalment 998 incidence odds and incidence odds
regulation 1070–1071 etiology/pathophysiology 998 ratios 15–16
polyuria and polydipsia 65–68 history and clinical signs 999 incidence rates 14–15
syndrome of inappropriate ADH public health implications 999 internal validity 8
secretion 1072–1073, 1072 treatment and prognosis 999 measures of association and effect
see also dehydration spot‐on lotions 1398 12–15
sodium bicarbonate infusion 1096 spotted fever and typhus group parametric versus nonparametric
sodium–calcium exchanger 177 Rickettsia 937–940 tests 10, 11
sodium–potassium exchanger clinical signs 938–939 prevalence 12–13
179–180 diagnosis 938–939 STE see speckle tracking
soft tissue sarcomas (STS) epidemiology 938 echocardiography
1333–1338 etiology/pathophysiology stents
canine 1334–1337 937–938 ureteral obstruction
diagnosis 1334 laboratory testing 939 1120–1121, 1120
epidemiology 1333 signalment 938 urethral obstruction 1115–1117,
etiology/pathophysiology 1333 sprays 1398, 1469 1116
feline 1337–1338 squamous cell carcinoma (SCC) urolithiasis 1153–1155,
history and clinical signs 1334 esophageal and stomach 1153, 1154
prognosis 1337–1338 cancers 1283 stereotactic radiation therapy
signalment 1334 male reproductive system (SRT) 47
treatment 1334–1337 tumors 1313–1314 stereotactic radiosurgery (SRS)
solid tumors 1207–1208 nonmelanoma skin approach to the cancer
solitary osseous plasmacytoma cancers 1354–1356 patient 1203
(SOP) 1241–1246 ocular adnexal tumors 1261–1263, bone and joint tumors 1331
somatomammotropic hormones 38 1262 central nervous system
SOP see solitary osseous plasmacytoma oral cavity and salivary glands tumors 1250
source control 427 539–541, 540 sterile granuloma/pyogranuloma
SPD see salmon poisoning disease oral tumors 1253–1256 syndrome (SGPS) 1446–1447
Spec‐fPL assay 603–605, 608 papillomaviruses 861–863 clinical signs 1446, 1446
speckle tracking echocardiography squamous metaplasia of prostatic diagnosis 1446–1447
(STE) 152, 162 epithelial cells 1163 pathogenesis 1446
